Caspase-cleaved tau protein (Asp421) (Tau-C3)

The delta tau neoepitope refers to a specific truncated form of the microtubule-associated protein tau, typically generated by caspase-3 or caspase-6 cleavage at the Aspartate 421 (D421) residue. This cleavage event creates a unique C-terminal neoepitope that is absent in full-length, healthy tau proteins. In neurodegenerative conditions such as Alzheimer's disease, this truncated tau species (often called Tau-C3) is highly pro-aggregatory and acts as a seed for the formation of neurofibrillary tangles. It is considered a potent neurotoxic agent that contributes to synaptic dysfunction and neuronal death. As a therapeutic target, the delta tau neoepitope is primarily addressed through passive immunotherapy using monoclonal antibodies designed to selectively bind and clear these pathological fragments without interfering with the normal function of full-length tau. This approach aims to halt the progression of tau pathology and preserve cognitive function in patients with tauopathies.

Other names

Delta tauD421-truncated tauCaspase-3 cleaved tauTau-delta-C421Truncated tau neoepitope

Passive immunization to facilitate the clearance of truncated tau species and prevent the seeding of neurotoxic tau aggregates.